Search Results for:
Natalie Leong
Ms. Leong has worked across four continents in valuation and transactions in sale, IPO, float, financial modeling, internal controls and raising capital. She has experience analyzing business plans, performing market analyses, preparing financial projections, developing valuation models, advising on equity transactions, mergers, acquisitions and corporate restructurings. Currently, Ms. Leong is Senior Vice President of Product Management for B.S.D Capital, Inc (d/b/a Lendistry). Previously, she held the positions of Head of Finance and Product Strategy and Head of Product Management for LoanStreet Inc. She was US lead for the Asset Liability Committee at RBC Capital Markets. At National Australia Bank, Ms. Leong was promoted to VP of Capital Insights. She has an MBA from Wharton School of Business, University of Pennsylvania, a BCom and a BA from the University of Melbourne.
James Culverwell
Mr. Culverwell has served as a director of Quoin Inc. since April 2021 and as a director of Quoin Ltd. since October 28, 2021. He is also currently serving as the Chief Executive Officer and Chairman of the Board of Directors of HOX Therapeutics. He serves as a director and Audit Committee Chairman of TC BioPharm (Holdings) plc (Nasdaq: TCBP) and he serves as a director, Audit Committee Chairman, and member of the Compensation Committee of SafeGuard Biosystems. In 2005, Mr. Culverwell founded Sudbrook Associates, which provided strategic advice and fundraising services for life science companies. Previously, Mr. Culverwell was Senior Vice President and Global Coordinator Healthcare Research at Merrill Lynch. He also served as Director of Healthcare Equity Research at ABN Amro Bank N.V., director and Audit Committee Chairman of Amryt Pharma PLC (Nasdaq: AMYT), and director and Audit Committee Chairman of Innocoll AG. He received an MSc with honors from the University of Aberdeen.
Joseph Cooper
Mr. Cooper has served as a director of Quoin Inc. since May 2021. With 30 years of pharmaceutical industry experience, Mr. Cooper has held roles in operational, corporate development and general management. He recently served as the Chief of Strategy and Corporate Development for Resonea, Inc., a digital health company. Formerly, he was President at Boulder Cove and Executive VP of Corporate and Product Development at Medicis Pharmaceutical. He also served as the Chief Business Officer of NuvOx Pharmaceuticals, a clinical stage pharmaceutical company and as Chief Financial and Operating Officer for First Place, AZ, a non-profit healthcare services organization. Mr. Cooper’s leadership experience is in clinical research, product development, supply chain, business development and executive management in a broad range of therapeutic areas including dermatology, aesthetics, allergy, sleep apnea, stroke and orphan drugs. Mr. Cooper currently serves as a director of Sonoran Biosciences, a specialty pharmaceutical company. He has also served as a director of Bioenvision (Nasdaq: BIVN). Mr. Cooper holds an MBA from the WP Carey School of Business at Arizona State University and a BA from Northeastern Illinois University.
Michael Sember
Mr. Sember has served as a director of Quoin Inc. since May 2021 and as a director of Quoin Ltd. since October 28, 2021. In his 40-year career, Mr. Sember has been COO or CEO of five diverse pharmaceutical companies ranging from drug discovery tool providers, to therapeutically-focused biotechnology companies, to medical devices. He served as Chief Executive Officer of RaeSedo, Inc., of Regulonix Holding, and of Palyon Medical Corporation. At Marion Laboratories (later Marion Merrell Dow) Mr. Sember handled roles including sales, research and R&D program management. As Executive VP of Business Development for Élan Corporation, he was responsible for strategic collaborations, mergers and acquisitions. Mr. Sember has consulted for numerous companies and has extensive public and private board experience. He has served as the Chairman of the Board of Paylon Medical Corporation and of BioIndustry Organization of Southern Arizona, a non-profit trade group. Currently Mr. Sember serves as Chair of the Screening Panel and Board member for the number-one-ranked Desert Angels, a Tucson, AZ-based group of angel investors. Mr. Sember earned a Bachelor of Science degree from the University of Pittsburgh and an MBA from Rockhurst University.